Skip to main content
. 2024 Jun 3;15:1414268. doi: 10.3389/fphar.2024.1414268

TABLE 7.

Time-of-treatment Reporting Odds Ratio (ROR) for commonly reported adverse events with Semaglutide

During PT a ROR ROR (95%Cl)
VOMITING PROJECTILE 11 54.44 54.44 (30.09–98.52)
KETOSIS 3 44.82 44.82 (14.42–139.36)
ERUCTATION 37 28.47 28.47 (20.59–39.36)
FOOD AVERSION 3 26.18 26.18 (8.43–81.31)
VITREOUS HAEMORRHAGE 5 22.71 22.71 (9.44–54.64)
EUGLYCAEMIC DIABETIC KETOACIDOSIS 5 20.45 20.45 (8.5–49.19)
DIABETIC RETINOPATHY 5 18.5 18.5 (7.69–44.49)
4 weeks VITREOUS DETACHMENT 3 17.77 17.77 (5.72–55.17)
PHARYNGEAL SWELLING 9 14.45 14.45 (7.51–27.81)
DIABETIC KETOACIDOSIS 27 14.22 14.22 (9.74–20.76)
NECK MASS 3 13.38 13.38 (4.31–41.54)
IMPAIRED GASTRIC EMPTYING 8 13.11 13.11 (6.55–26.24)
ILEUS PARALYTIC 4 11.47 11.47 (4.3–30.59)
HYPERAESTHESIA 8 11.43 11.43 (5.71–22.87)
PANCREATIC DISORDER 4 10.92 10.92 (4.1–29.12)
MEDULLARY THYROID CANCER 6 410.24 410.24 (182.31–923.15)
OBSTRUCTIVE PANCREATITIS 4 155.15 155.15 (57.92–415.59)
ALLODYNIA 4 98.06 98.06 (36.67–262.22)
FOOD AVERSION 5 65.61 65.61 (27.24–158.03)
PANCREATITIS CHRONIC 7 57.28 57.28 (27.25–120.41)
PANCREATIC CARCINOMA METASTATIC 8 50.1 50.1 (25.01–100.38)
PAPILLARY THYROID CANCER 4 45.59 45.59 (17.07–121.7)
>4 weeks MACULAR HOLE 3 42.43 42.43 (13.66–131.82)
CHOLECYSTITIS INFECTIVE 6 41.88 41.88 (18.78–93.38)
ADENOCARCINOMA PANCREAS 3 41.02 41.02 (13.2–127.44)
BILIARY COLIC 7 38.79 38.79 (18.46–81.51)
IMPAIRED GASTRIC EMPTYING 14 34.54 34.54 (20.42–58.42)
DIABETIC RETINOPATHY 6 33.33 33.33 (14.95–74.31)
THYROID MASS 6 32.37 32.37 (14.52–72.17)
LIPASE INCREASED 11 26.81 26.81 (14.83–48.49)

Note: a, number of cases with available; PT, preferred term.